含卡培他滨方案治疗复发转移性乳腺癌的临床观察

目的观察含卡培他滨方案对蒽环类和(或)紫杉类药物治疗后复发转移性乳腺癌的疗效和不良反应。方法 70例蒽环类和(或)紫杉类药物治疗后复发转移性乳腺癌患者分为两组,卡培他滨联合长春瑞滨(NX组,36例),卡培他滨800～1000mg/m2,分早晚两次服用,第1～14天,长春瑞滨25mg/m2,第1天和第8天,静脉滴注,3周为1个周期。卡培他滨联合吉西他滨(GX组,34例),卡培他滨800～1000mg/m2,分早晚两次服用,第1～14天,吉西他滨1g/m2,静脉滴注,第1天和第8天,3周为1个周期。每两个周期评价疗效,均至少治疗2个周期以上。结果 NX组患者中,完全缓1例(2.8%),部分缓解20例(55.6%),疾病稳定11例(30.6%),疾病进展4例(11.1%),有效率为58.3%,中位疾病进展时间13.5个月;完全缓解1例(2.9%),部分缓解19例(55.9%),疾病稳定12例(35.3%),疾病进展2例(5.9%),有效率为58.8%,中位疾病进展时间13.8月。常见的不良反应主要为骨髓抑制、胃肠道反应、手足综合征等。结论含卡培他滨方案治疗蒽环类和(或)紫杉类药物治疗后复发转移乳腺癌疗效确切,毒性可耐受,是治疗复发转移性乳腺癌的较好方案。

The effect of Capecitabine containing regimens on 70 cases of recurrent metastatic breast cancer

Objective To observe the efficacy and security of capecitabine-contained regimens for patients with recurrent metastatic breast cancer after docetaxel and anthracycline treatment.Methods A total of 70 cases were recruited.Thirty-six patients received NX regimen(NVB 25mg/m2 on day 1 and day 8,capecitabine 800-1000 mg·m-2·d-1,d1-14,repeated every 3 weeks.,in the GX(34) group capecitabine 800-1000 mg·m-2·d-1,d1-14,gemcitabine 1g/m2,on day 1 and day 8.The treatment was repeated every 3 weeks,two cycles at least.The efficacy was evaluated every 2 cycles.Results In the NX group,CR was achieved in 1 cases(2.8%),PR in 20 cases(55.6%),SD in 11 cases(30.6%),and PD in 4 cases(11.1%).The response rate in the NX group was 58.3%,in the GX group CR was achieved in 1 case(2.9%),PR in 19cases(55.9%),SD in 12 cases(35.3%),and PD 2 case(5.9%).The response rate in the GX group was 58.8%.The median time to progress was 13.5 months.in the NX group and 13.8 months in the GX group.The common toxicities included myelosuppression,gastrointestinal reactions and,hand-foot syndrome.Conclusions Capecitabine-contained regimens can achieve good results for recurrent metastatic breast cancer after docetaxel and anthracycline treatment,with tolerable side effects.